DDInter1297 DDInter1376
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Niraparib {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Niraparib {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Niraparib may lead to a major life threatening interaction when taken with Natalizumab
Niraparib may lead to a major life threatening interaction when taken with Baricitinib